Ligand Pharmaceuticals IncNASDAQ:LGND
- LAST PRICE84.7900
- TODAY'S CHANGE (%)-0.0600 (-0.0707%)
- Bid / Lots82.0300/ 1
- Ask / Lots87.6100/ 1
- Open / Previous Close84.8500 / 84.8500
- Day Range
- 52 Week Range
- Volume115,722
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LGND |
|---|---|---|
| 09:32 ET | 607 | 84.85 |
| 10:08 ET | 117 | 84.842 |
| 10:14 ET | 400 | 84.26 |
| 10:15 ET | 700 | 84.81 |
| 10:17 ET | 300 | 84.6 |
| 10:33 ET | 107 | 84.589 |
| 10:42 ET | 100 | 84.79 |
| 10:53 ET | 100 | 84.89 |
| 10:55 ET | 300 | 84.98 |
| 10:57 ET | 200 | 85.35 |
| 11:04 ET | 678 | 85.115 |
| 11:06 ET | 100 | 84.82 |
| 11:11 ET | 863 | 85.11 |
| 11:24 ET | 100 | 84.61 |
| 11:26 ET | 100 | 84.94 |
| 11:36 ET | 255 | 84.63 |
| 11:38 ET | 100 | 84.78 |
| 11:42 ET | 100 | 84.805 |
| 11:47 ET | 154 | 84.8183 |
| 11:49 ET | 100 | 84.805 |
| 11:54 ET | 3720 | 85.24 |
| 11:58 ET | 100 | 85.26 |
| 12:00 ET | 287 | 85 |
| 12:02 ET | 600 | 85 |
| 12:03 ET | 1680 | 85.42 |
| 12:09 ET | 305 | 85.31 |
| 12:23 ET | 100 | 85.215 |
| 12:27 ET | 100 | 85.09 |
| 12:34 ET | 881 | 85 |
| 12:36 ET | 2000 | 85.21 |
| 12:38 ET | 200 | 85.197 |
| 12:43 ET | 100 | 85.025 |
| 12:50 ET | 100 | 85.025 |
| 12:52 ET | 100 | 85.15 |
| 12:56 ET | 100 | 85.2 |
| 01:01 ET | 700 | 85.22 |
| 01:03 ET | 925 | 85.15 |
| 01:06 ET | 100 | 85.025 |
| 01:10 ET | 100 | 85.25 |
| 01:32 ET | 122 | 85.118 |
| 01:39 ET | 2000 | 85.188 |
| 01:55 ET | 100 | 85.005 |
| 02:00 ET | 100 | 85.14 |
| 02:02 ET | 100 | 85.15 |
| 02:04 ET | 300 | 85.1 |
| 02:06 ET | 200 | 85.12 |
| 02:08 ET | 100 | 85.145 |
| 02:09 ET | 556 | 85.225 |
| 02:22 ET | 100 | 85.22 |
| 02:29 ET | 400 | 85.457 |
| 02:31 ET | 1386 | 85.34 |
| 02:36 ET | 700 | 85.51 |
| 02:38 ET | 100 | 85.61 |
| 02:47 ET | 898 | 85.41 |
| 03:02 ET | 342 | 85.13 |
| 03:03 ET | 946 | 85.13 |
| 03:07 ET | 100 | 84.99 |
| 03:12 ET | 2548 | 85.12 |
| 03:20 ET | 300 | 85 |
| 03:23 ET | 100 | 85.25 |
| 03:30 ET | 200 | 85.25 |
| 03:32 ET | 300 | 85.35 |
| 03:34 ET | 300 | 85.39 |
| 03:36 ET | 400 | 85.47 |
| 03:38 ET | 1338 | 85.16 |
| 03:39 ET | 300 | 85.232 |
| 03:41 ET | 1089 | 85.275 |
| 03:43 ET | 100 | 85.397 |
| 03:45 ET | 400 | 85.397 |
| 03:48 ET | 422 | 85.28 |
| 03:50 ET | 200 | 85.38 |
| 03:52 ET | 300 | 85.44 |
| 03:54 ET | 1100 | 85.49 |
| 03:56 ET | 3838 | 84.91 |
| 03:57 ET | 1600 | 84.8 |
| 03:59 ET | 4224 | 84.79 |
Yesterday
Lifecore Biomedical Announces Cooperation Agreement with 22NW, from 8:00AM ET on Monday Jul 01, 2024 by Dow Jones
8:00AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 28, 2024
DJ Ligand Pharmaceuticals Price Target Maintained With a $95.00/Share by Benchmark, from 10:25AM ET on Friday Jun 28, 2024 by Dow Jones
10:25AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
DJ Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co., from 11:56AM ET on Thursday Jun 27, 2024 by Dow Jones
11:56AM ET on Thursday Jun 27, 2024 by Dow JonesLigand Partner Verona Pharma Announces FDA Approval of Ohtuvayre(TM) (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years, from 8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 18, 2024
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE(TM) (Pneumococcal 21-valent Conjugate Vaccine) for Adults, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ligand Pharmaceuticals Inc | 1.5B | 16.2x | -12.71% |
Avadel Pharmaceuticals PLC | 1.4B | -7.5x | --- |
Harrow Inc | 744.8M | -23.0x | --- |
Ocular Therapeutix Inc | 1.0B | -6.1x | --- |
Immunocore Holdings PLC | 1.8B | -29.0x | --- |
SIGA Technologies Inc | 537.0M | 7.1x | -28.78% |
Company Information
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Contact Information
- Headquarters
- 555 Heritage Drive, Suite 200JUPITER, FL, United States 33458
- Phone
- 858-550-7500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- John Kozarich
- President, Chief Operating Officer
- Matthew Korenberg
- Chief Executive Officer, Director
- Todd Davis
- Chief Financial Officer
- Octavio Espinoza
- Chief Legal Officer
- Andrew Reardon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $118.3M |
Shares Outstanding | 18.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $5.23 |
Book Value | $39.92 |
P/E Ratio | 16.2x |
Price/Sales (TTM) | 12.9 |
Price/Cash Flow (TTM) | 11.5x |
Operating Margin | -2.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
